The aim of the present study was to use a combinatorial approach of inclusion complexation
and dendrimer synthesization of gefitinib using solvent-free technique for targeting EGFR-TK …

Due to its poor solubility and systemic side effects, gefitinib (Gef) has limited application in
treatment of lung cancer. In this study, we used design of experiment (DOE) tools to gain the …

Lung cancer is the main cause of cancer-related mortality globally. Erlotinib is a tyrosine
kinase inhibitor, affecting both cancerous cell proliferation and survival. The emergence of …

Since lung cancer is the most malignant cancer today, a specific drug-delivery system has
been developed for superior outcome. In this study, gelatin nanoparticles (GPs) employed …

Gefitinib (GEF) is the first epidermal growth factor receptor (EGFR)-targeting agent launched
as an anticancer drug. It is an accepted opinion that modifying GEF strong hydrophobicity …

Lung cancer is the most malignant cancer today, and specific drug delivery has been
developed for superior outcome. In this study, gelatin nanoparticles (GPs) were firstly …

Epidermal growth factor receptor (EGFR) normally over-expresses in non-small cell lung
cancer (NSCLC) cells. Its mutations act as oncogenic drivers in the cellular signal …

The present study was aimed at developing and exploring the use of long circulating
biocompatible PEGylated PPI 5.0 G den-drimers for delivery of an anti-cancer drug, Imatinib …

Background: Gefitinib (GFN) is an Epithelial Growth Factor Receptor (EGFR) inhibitor, and
Food and Drug Administration (FDA) has approved medication to treat lung cancer …

Introduction This study aims to develop a novel co-delivery gefitinib and quercetin system
loaded with PLGA-PEG nanoparticles and evaluate their antitumor activity in vitro and in …